Bringing a prophylactic Ebola vaccine to licensure
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost pro...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EBOVAC2
Development of a Prophylactic Ebola Vaccine Using an Heterol...
51M€
Cerrado
VSV-EBOVAC
Vaccine safety and immunogenicity signatures of human respon...
5M€
Cerrado
VSV-EBOPLUS
SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV...
15M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:
A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.